LENZ Therapeutics (LENZ) TD Cowen 46th Annual Health Care Conference summary

Launch overview and early performance

• Presbyopia eye drop launched in October after August approval, targeting reading glasses replacement.

• Product demonstrates strong efficacy in both clinical trials and real-world use, with up to 10+ hours of near vision improvement.

• Sampling strategy distributed to 15,000 target doctors, leading to high trial and conversion rates.

• Growing patient and doctor base, with over 6,500 prescribing doctors as of January and rapid expansion since.

• Expansion of sales force underway to meet increasing demand and broaden reach.

Efficacy, safety, and patient experience

• Efficacy consistently reported as strong, with many users experiencing 11-12 hours of benefit.

• Side effects such as mild, transient hyperemia and rare headaches are well-managed and communicated.

• Only one reported case of retinal tear, attributed to a patient with pre-existing conditions; no impact on prescribing trends.

• Product considered safe by key opinion leaders, with no evidence of increased risk compared to background rates.

Commercial strategy and market development

• Direct-to-consumer (DTC) campaign launched in January, featuring Sarah Jessica Parker as spokesperson.

• DTC efforts expected to take two quarters to fully impact prescription growth; early signals are positive.

• Website traffic and patient inquiries have increased significantly, indicating rising awareness.

• Sales force expansion aims to increase frequency and quality of clinician engagement.